Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HTR2B | P41595 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7733992 | 0.89 | NOTUM (0.55) | NOTUMMEN1MAPTKMT2ALMNA | |
| SCHEMBL811795 | 0.89 | NOTUM (0.55) | NOTUMMEN1MAPTKMT2ALMNA | |
| SCHEMBL6890897 | 0.89 | NOTUM (0.55) | NOTUMMEN1MAPTKMT2ALMNA | |
| SCHEMBL31672940 | 0.89 | NOTUM (0.55) | NOTUMMEN1MAPTKMT2ALMNA | |
| Ammonia Solution, Strong SCHEMBL29093479 | 0.87 | NOTUM (0.53) | NOTUMMEN1MAPTKMT2ALMNA | |
| Hydrochloric Acid SCHEMBL28861795 | 0.87 | NOTUM (0.53) | NOTUMMEN1MAPTKMT2ALMNA | |
| SCHEMBL27711736 | 0.86 | NOTUM (0.50) | NOTUMMEN1MAPTKMT2ALMNA | |
| SCHEMBL8516304 | 0.75 | NOTUM (0.53) | NOTUMMEN1MAPTKMT2ALMNA | |
| SCHEMBL23346693 | 0.72 | AADAT (0.44) | NOTUMHTR2AHTR2CHTR2B | |
| SCHEMBL13070447 | 0.72 | NOTUM (0.53) | NOTUMMEN1MAPTKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115433116-B | Acylated indoline derivative, composition and application thereof | 徐州医科大学 | 2023-07-14 | — | — | CN | claimed |
| CN-115521302-A | Tetrahydro (iso) quinoline or indoline derivative, composition and application thereof | 徐州医科大学 | 2022-12-27 | — | — | CN | claimed |
| CN-115433116-A | Acylated indoline derivative, composition and application thereof | 徐州医科大学 | 2022-12-06 | — | — | CN | claimed |
| CN-115433116-B | Acylated indoline derivative, composition and application thereof | 徐州医科大学 | 2023-07-14 | — | — | CN | disclosed |
| CN-116249690-A | Indoline compounds and derivatives as EGFR inhibitors | 百济神州有限公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-115894325-A | Derivative containing aryl piperazine structure, composition and application thereof | 徐州医科大学 | 2023-04-04 | — | — | CN | disclosed |
| CN-115521302-A | Tetrahydro (iso) quinoline or indoline derivative, composition and application thereof | 徐州医科大学 | 2022-12-27 | — | — | CN | disclosed |
| CN-115433116-A | Acylated indoline derivative, composition and application thereof | 徐州医科大学 | 2022-12-06 | — | — | CN | disclosed |
| CN-114748622-A | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | 弗尔康医疗公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114732910-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-111601593-B | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-111601593-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2020-08-28 | — | — | CN | disclosed |
| EP-2643311-A1 | BICYCLIC GPR119 MODULATORS | Lupin Limited (IN) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012069917-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1490064-B1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-1490064-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | Pharmacia Corporation (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | NOTUM 3993/4885MEN1 4261/4885MAPT 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.